Back to search results

Panitumumab-IRDye800 for Detecting Lung Cancer During Surgery

This study is testing a new way to help surgeons find lung cancer during an operation. It uses a drug called panitumumab-IRDye800, which combines a known antibody drug (panitumumab) with a special dye (IRDye800CW) that glows under a special camera. The goal is for panitumumab-IRDye800 to attach to cancer cells, making them easier to see. Researchers want to find the best dose and timing for this drug to highlight lung tumors compared to healthy tissue. You might be able to join if you have a lung nodule or mass that doctors suspect is cancer, or if you have lung cancer that has spread, and you are scheduled for surgery. The study aims to see if this method is safe and effective in making tumors more visible during surgery.

Study design
This is a Phase 1/2 study that will enroll 30 participants. It starts by testing different doses of panitumumab-IRDye800.
What's involved
You would receive panitumumab-IRDye800 through an IV, then undergo special imaging and surgery within 1 to 5 days.
Compensation
Not stated in the trial record.
Follow-up
After your treatment, you would be followed for up to 30 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03582124

Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

Recruiting
PHASE1Ages 19+InterventionalDiagnostic
Stanford University
~30 participants
Updated 2026-02-10 on ClinicalTrials.gov
What's tested:Near-Infrared Fluorescence ImagingPanitumumab-IRDye800Pharmacokinetic StudyTherapeutic Conventional Surgery

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Tumor to background ratio (TBR), measured in ex vivo tissues
Measured over Up to 1 year

Conditions

Lung Carcinoma
Metastatic Malignant Neoplasm in the Lung
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Explore related trials

Lung Carcinoma

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Natalie Lui · PRINCIPAL_INVESTIGATOR · Stanford University

Who to contact

Natalie Lui
[email protected]
650-721-2086
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with lung nodule or mass concerning for malignancy, either primary lung cancer or lung metastases, whether or not it is biopsy-proven
Patients scheduled to undergo planned standard of care surgical resection for a lung nodule or mass with diagnostic and/or curative intent for lung cancer
Karnofsky performance status of at least 70% or Eastern Cooperative Oncology Group (ECOG)/Zubrod level 0-2
Hemoglobin ≥ 9 gm/dL
White blood cell count \> 3000/mm\^3
Platelet count ≥ 100,000/mm\^3
Serum creatinine ≤ 1.5 times upper reference range

Exclusion

Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800
Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment
History of infusion reactions to monoclonal antibody therapies
Pregnant or breastfeeding
Magnesium or potassium lower than the normal institutional values
Subjects receiving class IA (quinidine, procanamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents
Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis
Prisoners, institutionalized individuals, and patients unable to consent for themselves

What this trial measures

  • Tumor to background ratio (TBR), measured in ex vivo tissuesUp to 1 year

    The TBR is defined as the near-infrared fluorescence signal of tumor or lymph node tissue compared to normal adjacent tissue measured in ex vivo tissues. Outcomes will be reported as the TBR (mean) and standard deviation for each dose group and timing group (1-2 days or 3-5 days prior to surgery).